273 related articles for article (PubMed ID: 30975761)
41. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
[TBL] [Abstract][Full Text] [Related]
42. Integrated Histogenetic Analysis Reveals
Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
[TBL] [Abstract][Full Text] [Related]
43. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
44. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
Ugurluer G; Chang K; Gamez ME; Arnett AL; Jayakrishnan R; Miller RC; Sio TT
Anticancer Res; 2016 May; 36(5):2331-8. PubMed ID: 27127140
[TBL] [Abstract][Full Text] [Related]
45. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
46. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
47. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
[TBL] [Abstract][Full Text] [Related]
48. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
49. Germline BAP1 mutations and tumor susceptibility.
Goldstein AM
Nat Genet; 2011 Sep; 43(10):925-6. PubMed ID: 21956388
[TBL] [Abstract][Full Text] [Related]
50. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
51. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract][Full Text] [Related]
52. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
Zauderer MG
Nat Commun; 2021 Mar; 12(1):1819. PubMed ID: 33753750
[TBL] [Abstract][Full Text] [Related]
53. [Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
[TBL] [Abstract][Full Text] [Related]
54. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
[TBL] [Abstract][Full Text] [Related]
56. Puzzling Results from
Rizzardi C; Athanasakis E; Cammisuli F; Monego SD; DE Spelorzi YCC; Costantinides F; Giudici F; Pinamonti M; Canzonieri V; Melato M; Pascolo L
Anticancer Res; 2017 Jun; 37(6):3073-3083. PubMed ID: 28551647
[TBL] [Abstract][Full Text] [Related]
57. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
58. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
59. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
[TBL] [Abstract][Full Text] [Related]
60. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
Panou V; Gadiraju M; Wolin A; Weipert CM; Skarda E; Husain AN; Patel JD; Rose B; Zhang SR; Weatherly M; Nelakuditi V; Knight Johnson A; Helgeson M; Fischer D; Desai A; Sulai N; Ritterhouse L; Røe OD; Turaga KK; Huo D; Segal J; Kadri S; Li Z; Kindler HL; Churpek JE
J Clin Oncol; 2018 Oct; 36(28):2863-2871. PubMed ID: 30113886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
